Lithuania's Life Sciences industry overview

Lithuania's Life Sciences industry overview

Key facts

Lithuania is well estabilshed in international rankings and is listed together with the most developed countries:

- **4**th position in Europe (**12**th globally) **Economic Freedom Ranking**

Source: Fraser Institute, 2022

- The **8**th in **International Tax Competitiveness Index** Rankings among 36 OECD countries

Source: International Tax Competitiveness Index Rankings, 2022

- The **4**th in **CEE** in **Innovation Scoreboard** 2022 with the highest strengths in Linkages, Digitalization, and Innovators

Source: European Commission, 2022

- The **39**th in the **World Innovation Index** among 132 countries

Source: World Intellectual property Organization, 2022

- The **2**nd globally in the **talent competitiveness ranking** in the GDP per capita less than $20,000 country category

Source: IMD World talent ranking, 2021

- The **10**th in **ICT adaptation** globally

Source: World Economic Forum, 2020

- The **1**st in **Gender Gap Index** CEE countries (**11**th globally)

Source: World Economic Forum, 2022

- The **24**th position out of 193 countries in the **E-Government Development Index**

Source: UN Department of Economic and Social Affairs, 2022

- The **2**nd in **National Cyber Security Index** worldwide

Source: National Cyber Security Index (E-Governance Academy), 2022

- In 2020, Lithuania's real GDP shrank only by 0.8% and it was the **2**nd **lowest GDP decline** across the EU due to **Covid-19 pandemics**

Source: World Economic Forum, 2020

- **1**st in the EU according to the **2022 Greenfield FDI Performance Index**. Given the size of Lithuania's economy, it attracts 5.7 times more projects than the size of its GDP would suggest.

Source: FDI Intelligence, 2022

Life Sciences – booming sector of Lithuania's economy

Life Sciences – government priority. In 2018, the government set Life Sciences as a priority sector, with an ambitious strategic goal to achieve 5% of GDP by 2030. Lithuania's life sciences sector grew by 22% during 2022 and accounts for about 2.7% of GDP (Source: LBTA, 2023).

Life Sciences community. Agile and tight-knit Lithuania's innovation ecosystem is a real community where solutions are quick, and networks are instant. A close and supportive community is often cited by life sciences companies as a draw to Lithuania.

Life Sciences production export. Lithuania's geographical position creates a convenient location for companies willing to manufacture their pharmaceutical products. For instance, 90 % of all Life Sciences manufactured products are exported. The main export markets are the USA (18,7%), Poland (8%), Germany (7,4%), China (7,4%), the UK (6,5%), and others (52,1%) and a growing export balance of Asian countries specifically South Korea, Japan(Source: Statistics Lithuania, 2020).

Life Sciences sector profile. The Life Sciences sector in Lithuania is divided into two main subsectors: biotechnology & pharma, and medical devices/ MedTech.

Lithuania's Life Sciences industry overview

Life Sciences hub

Life Sciences hub. Two cities Vilnius and Kaunas are forming the Life Sciences hub, which is boosted by an integrated network of science valleys and educational institutions supplying businesses with an educated and motivated talent pool. The capital Vilnius was ranked 2nd after Zurich in the mid-sized cities category of the Cities of the future ranking by fDi intelligence.

Key R&D hubs

Santaka Science Valley

- National Entrepreneurship and Innovation Centre
- Technology Transfer Centre
- 9 Research Institutes

- Advanced research in organic chemistry, medical technologies, nanotechnologies, robotics

Santara Science Valley

- 5 research institutes and 4 private R&D facilities
- 3 GMP-compliant pharma plants
- Academic training centers and open labs
- Vilnius City Innovation Industrial Park (VCIIP)
- Advanced research in medicine, physics, chemistry and biochemistry photonics, nanotechnologies

Comparison of Vilnius & Kaunas

	Vilnius	Kaunas
Facts	• Capital city • Population of 829 759 (2021) • Unemployment rate 8,9% (2022) • Average gross salary across all industries 1 972 EUR* (2022)	• 2nd biggest city in Lithuania • Population of 565 592 (2021) • Unemployment rate 9,5% (2022) • Average gross salary in all industries 1 695 EUR* (2021 Q4)
Exposure of talent	Vilnius is driven by STEM oriented young, multi-lingual talent pool	Kaunas population is comprised of a mix of blue-collar and white-collar employees
LS profile	**Pharmaceutical and biotech** Present companies: Thermo Fisher Scientific Baltics, NorthwayBiotech, Teva, Froceth, Caszyme	**Medical devices and hardware tech** Present companies: Hollister, Esco Medical Technologies, Kitron, KB Components, Gruppo FOS
Other present industries	**Global Business Services and Fintech** Dexcom, AmerisourceBergen, McKesson, Revolut, TransferGo and others	**Manufacturing and engineering** Continental, Hella , and others

Lithuania's Life Sciences industry overview

Biotechnology & Pharma in Lithuania

Biotechnology sector potential. Biotechnology is one of Lithuania's fastest-growing sectors, with a growth rate significantly above the European average, amounting to 87% during 2020 (Statistics Lithuania, 2020). Biotechnology is also one of the priority sectors of the Lithuanian economy. The Lithuanian smart specialization strategy, which sets out the priorities for research, experimental development and innovation, also distinguishes biotechnology along with health technologies which implies constant Government attention and support to biotechnology ecosystem in Lithuania.

50th Biotechnology anniversary celebration. In 2021 Lithuania's biotechnology sector was celebrating 50 years. At the beginning of 1971, the first enzyme factory opened in Vilnius. Out of five being built in the USSR territory at that time, it was the first one to start its operations. A research center was opened in this factory in the summer same year. This factory gave the biotechnology sector in Lithuania a strong foundation, which is now one of the most productive and fastest-growing economic sectors in the country.

Key competencies. The main sectors' competencies lie in cell & gene therapies, bio-pharma, and enzymes. Enzymology has been a historical strength of Lithuania since the 1970s when Lithuania was chosen to be the center for enzymology in the region. At that time, several spin-offs were created, such as Northway Biotech, Fermentas, and Sicor Biotech. The past two were later acquired by global players - Thermo Fisher Scientific and Teva.

Emerging sector - PharmTech. Reaping the benefits of booming tech sector, Lithuania is becoming a hub for new generation AI driven healthcare startups looking for a world-class ICT talent pool.

Cell and Gene therapies – booming subsector

One of the most promising biotechnology subsectors in Lithuania – cell & gene therapies (hereinafter – CGT). The subsector has emerged in recent years and has promising potential for further growth.

CGT competences. First and foremost, the key driver of the subsector lies down to strong scientific academia in Lithuania. Cell and gene therapy competencies are present in three major universities: Vilnius University (VU), Vilnius Magnus University, and Lithuanian University of Health Sciences (LSMU). The main programs are human and molecular genetics, and human genome analysis with a strong focus on genetic testing. Graduates' skills and capabilities are applied in health care institutions and scientific laboratories, where their research and practical expertise become key to the successful development of new products. Talented students proved globally their proficient competencies by being awarded as the best team in the most prestigious international Synthetic Biology competition "International Genetically Engineered Machine (iGEM)" twice, in 2017 and 2020.

CGT cluster. The CGT cluster in Lithuania unites a well-developed start-ups ecosystem. For instance, Caszyme, a start-up established by prof. Virginijus Siksnys and his team, who were the first to prove that CRISPR-Cas9 enzymes can be used to operate precise double-strand breaks in DNA, thereby ushering in a new era of gene editing was established in the Life Sciences Center in 2017. The company has recently partnered with New England Biolabs and Corteva Agriscience to explore biochemically diverse Cas9 orthologs. The Professor Siknys is recognized within the sector globally and has received the Kavli Prize in 2018 for the gene-editing nanotool.

Lithuania enjoys membership in the European elite club in molecular biology. The availability of a strong talent pool and yet unsaturated market plays a major role for the companies developing their products in the country. To further foster the research capabilities in the country, in 2020 Prof Edith Heard (EMBL) signed an agreement with Vilnius University (VU) on the establishment of a Partnership Institute in the Life Sciences Centre (LSC) of Vilnius University with the focus primarily on the advancement in genetic editing technologies. Being one out of the six total locations in Europe, the establishment of an elite molecular biology laboratory unit in Lithuania is extremely significant not only for the University, but this also shows the international acknowledgment of the entire Lithuanian life sciences sector. This partnership opened even more opportunities for Lithuania to implement competitive research and innovations in the international arena.

Lithuania's Life Sciences industry overview

Focus on future technologies : AI in drug discovery

Embarking on the evolution of the entire industry, Lithuania is offering centralized patient data and high-level tech talent to biopharma companies interested in piloting their AI-related projects locally.

Data has been collected within Lithuanian healthcare nationally for more than 20 years. In 2015, ESPBI IS, a centralized national health record system that serves as the foundation for the country's entire electronic healthcare ecosystem, was created. The data collected extends beyond the national patient registry to include a broad range of data points, from the birth registry, diagnosis of diseases and illness progressions through routine visit documentation. Using the latest data exchange standard, the system interconnects a wide variety of different stakeholders: from doctors to patients.

Sharing and re-using health data for research purposes. Lithuania, in line with the wider EU's legislation plan, passed the law allowing companies to access citizens' health data. A pilot version of the open data portal data.gov.lt, has been active for R&D-driven businesses since June 2020. Open data sets are constantly updated alongside maps of data and interfaces of the portal. Companies can also request specific data sets based on their research requirements.

ICT Talent. Lithuania has 52k ICT specialists employed and is a leading country in Europe for ICT specialists having tertiary education, 2nd in students choosing STEM studies and 4th by young specialists (age 15 – 34) joining ICT sector. Lithuania's IT talent pool primarily comes from 3 streams: universities (10,6k IT students enrolled in IT studies, ~2000 IT students graduate each year), private coding academies (~2500 people requalify as junior developers through private coding schools each year), positive migration trends (~4000 IT specialists moved to Lithuanian from non-EU countries in 2022 alone).

Enthusiasm for AI. Lithuania is 4th in the EU for enterprises using at least two AI technologies. Lithuania has a strong AI community with an ever-evolving AI ecosystem. There are regular AI meetups gathering hundreds of participants. Some Lithuanian AI companies and startups have really shined and are helping to discover Lithuania as a country of AI developers. „Artificial Intelligence Association of Lithuania" - a community of professionals and enthusiasts dedicated to promoting and encouraging AI integration and development.

Key local enterprises: Baltic Amadeus, Neurotechnology, Magma solutions (Pixevia), Vilantis, Telesoftas, Easyflow, 1T2B, Agmis. Foreign: Satalia, InData Labs, Beyond Analysis, Jaydevs and others.

Lithuania's Life Sciences industry overview

Regulatory environment

Regulatory authorities. Being a member of the European Union, Lithuania falls under European Medicine Agency regulations. Local authority State Medicines Control Agency (SMCA) is fully integrated within the EU regulatory system. Also, Lithuania has Mutual Recognition Agreement with FDA which provides foreign companies with an opportunity to apply for FDA approval with clinical trials data collected in Lithuania. Thus, making the drug approval process more efficient and convenient to cover both EU and USA markets at once.

Exceptional regulatory environment. Lithuania offers an exceptional regulatory environment for clinical trials, called hospital exemption, which allows hospitals and medical practitioners to provide ATMP classified products (including gene therapy medicinal products, somatic cell therapy medicinal products, and tissues engineered products) to patients, e.g., in case of high unmet medical need because there is no authorized ATMP alternative available. This exemption provides a mechanism for companies to apply products, and in parallel collect data for final approval which is an attractive and time-saving opportunity for companies allowing to start applying therapies before marketing authorization is granted.

Clinical trials in Lithuania

Lithuania offers a favorable business environment to conduct clinical trials. Over 90 international pharma and medical companies are already conducting clinical trials in the country, with Phase III being the most popular phase with the main research areas being gastroenterology, oncology, and endocrinology. It takes less than 60 days to receive approval to conduct the clinical trial in the country.

Clinical Trials in Lithuania

FDA Part of the Clinical Trial MRA since 2018

Top 10 companies carrying out Clinical Trials

abbvie | SANOFI | BAYER | NOVARTIS
Roche | Celgene | janssen
ARENA PHARMACEUTICALS | Lilly | REGENERON

658 CT ongoing 2021

Phases
- I
- II
- III
- IV

1.2%
5.3%
18.7%
74.8%

Sources: Clinical Trials Board of Lithuania, 2020; EU Clinical trials register, 2021

Clinical Trials in Lithuania

Why choose Lithuania as a location to conduct Clinical Trials?

- Being part of Eastern Europe, Lithuania represents largest patient population in Europe
- Excellent patient recruitment rates
- Proven Clinical Quality Standards (FDA mutual agreement, EMA)
- Lower density of Clinical Trials in the region
- Competitive per patient costs

On average it takes 6-7 weeks from Clinical Trials application submission to approval in Lithuania

Clinical Trial Centers and Expertise

25% CT
Santara Clinics
Vilnius

>180
Highly-skilled PIs

23% CT
Kaunas Clinics
Kaunas

8% CT
Klaipeda University Hospital
Klaipeda

Therapeutic areas:

Gastro-enterology | Chron's Disease | Ulcerative Colitis | Other
Autoimmune | Arthritis | Other | Lupus
Cardiovas.
Oncology | Prostate | Solid Tumours | Other | Lung | Uterus | Other | Neuro | Endocrine
Infectious Disease

Clinical Trials Board of Lithuania, 2020

Lithuania's Life Sciences industry overview

Talent pool

The talent pool overview. 94.9% of the population with upper secondary, post-secondary or tertiary education. Lithuania has a sizable academically trained population and the employment rate of tertiary-educated young adults in Lithuania is the highest across the EU at 93% (OECD Employment, 2020). Lithuania has an above-average number of graduates per 1,000 population in STEM (science, technology, engineering, and mathematics) subjects (Eurostat 1, 2020).

Universities. There are 4 major Life Sciences universities. Two of them are located in the capital - Vilnius University, Vilnius tech, other two in the second-largest city Kaunas - Lithuanian University of Sciences and Kaunas University of Technology. The main programs at the universities are pharmaceutical/medicinal chemistry, biochemistry, molecular biology, biology, bioengineering, biotechnology, applied chemistry, chemical/bio/electronics engineering.

Innovation oriented. Lithuania is ranked 2nd globally by Bloomberg for 'tertiary efficiency' which includes enrolment in higher education and the number of graduates in key innovation sectors (Source: Bloomberg Innovation Index, 2020).

Women in science. According to Eurostat, women make up 58% of all researchers in Lithuania. In order to further promote women's leadership in both the biotechnology and life sciences sector, the Lithuanian Biotechnology Association organizes the platform Women in Biotech where world-renowned leaders in their field share inspiring thoughts on leading in the life sciences sector.

An example of women's leadership in science is highly represented by Vilnius University Life Science Centre scientists dr. Ieva Plikusiene and Joana Smirnoviene who were awarded the prestigious L'Oréal-UNESCO Baltic "For Women in Science" fellowship in June 2021 and 2022. Lithuanian scientists were awarded for their contribution to scientific progress in a wide range of fields, from the development of smart materials for cancer treatment to tackling the COVID-19 pandemic.

Infrastructure

Physical connectivity. Lithuania's geographical position creates a convenient location for export. Developed road & rail, air and sea infrastructure guarantee fast production connection to the remaining parts of Europe, Asia and America. Moreover, the new Rail Baltica project not only willl connect the Baltic region with a train track but will unify it to the European standard.

R&D infrastructure. Understanding the importance of infrastructure for the sector to grow, the Lithuanian government has invested significantly in open R&D infrastructure – about 1 billion EUR (2006-2020) and 1 billion to be invested further for both the infrastructure and R&D activities.

Vilnius City Innovation Industrial Park (VCIIP) is an industrial park in the capital of Lithuania, dedicated exclusively to the development of innovative business. The park, which has been operating since August 2018, has already attracted more than 67 million investments. In the future, 30 companies are planning to establish themselves in the industrial park, most of them will develop projects in the field of life sciences. The importance of gathering strong life science companies and science centers of different profiles is evident – this park will serve as a science hub to develop products and innovations competing at the global level.

Aleksotas Innovation Industrial Park (AIPP) - the compact, green and communication-promoting innovation valley in the heart of the Aleksotas microdistrict. It will not only comply with the modern principles of sustainable development and significantly stimulate the economic and innovation development of the Kaunas region, but will also attract investment capital and talents from Lithuania and abroad. Here, innovative companies will be able to operate successfully, cooperate with scientific institutions and create added value for the whole country.

Lithuania's Life Sciences industry overview

Lithuania has created a supportive and open startup ecosystem, which is eager to support start-ups and future entrepreneurs. The country has active local investors and supportive governmental institutions environment. Start-ups have a number of co-working spaces and hubs, sandboxes, and plenty of other ecosystem players that could offer partnership and support. The start-up ecosystem in Lithuania has helped to emerge many Life Sciences companies, just to mention a few:

Oxipit – a startup that developed ChestEye — the first AI chest X-Ray radiology suite for healthy patient reports . Oxipit closed a $4.9M funding round led by Taiwania Capital, Practica Capital, and Coinvest Capital.

Biomatter Designs – pioneering the technologies for generative protein design at the intersection of synthetic biology and AI. They are working to develop experimental tools for the efficient collection of biological data. The company's generative AI is explicitly tailored for protein science, allowing massive amounts of data to be translated into usable knowledge.

Kilo health - was founded in 2013 in Lithuania. The company is an investor and developer of over 15+ products. It aims to spur new growth in the digital health space by creating new tech products an d helping startups in the industry grow. Over the past 3 years Kilo Health has grown by 450.05% and has more than 4 million customers. It has more than 500 employees, and offices across 5 European cities. As of 2022, Kilo Health is the second fastest-growing company in Europe on the FT 1,000 ranking, the second-fastest growing company in Central Europe on the Deloitte Technology Fast 50 list,

Droplet Genomics – designs microfluidic instruments, consumables, and data analysis tools, so biological samples can be analyzed at the granularity of single cells.

Rubedos – developed unmanned missioning and computer vision solutions for industrial applications since 2009. The company provides hardware, software, and services to enable self-driving vehicle development, deployment and fleet operation. Rubedo can convert customer-selected vehicle platforms into robotic systems.

Softneta – specializes in medical imaging and communication solutions to improve the quality of healthcare. The company was founded in 2007 and possesses 14+ years of experience in the development of medical devices for processing, visualization and transmission of diagnostic medical data.

Ligence – develops machine learning algorithms that are capable of automatically detecting a person's heart functional and anatomical features from ultrasound images.

Sentiance – a data science company turning sensor data into rich insights about people's behavior. Their technology goal is to enable companies to understand how customers go through their everyday lives, discover and anticipate the moments that matter most, and adapt their engagement to real-world behavior and real-time context. Sentiance's technology is primarily used in insurance, health, and mobility applications.

Sentante - creates smart, sensory, teleoperated robot systems which allow the procedure to be performed remotely, from a different room, thus protecting physicians from harmful X-rays and opening up tele-surgery possibilities.

SynHet - a research-based manufacturer and worldwide supplier of combinatorial building blocks, screening compounds, organics and fine chemicals.

Lithuania's Life Sciences industry overview

Cost to quality ratio

Excellent cost to quality ratio. The quick ramp-up of the business in Lithuania is strongly influenced not only by the government support and complete ecosystem but also because of the cost to quality ratio. Considering the hypothetical scenario, that a company expands and opens a Biotech – Pharma Manufacturing facility in Lithuania and a team of 150 qualified people is hired, the total average annual labor costs for running a facility is approx. 2 to 4 times lower than in Spain, the UK, Ireland and Germany (Source: FDI Benchmark, 2021). This proves the competitiveness of establishing operations in Lithuania.

Financial incentives

Free Economic Zones. Lithuania has seven Free Economic Zones in various locations across the country. These provide unbeatable conditions to develop businesses by offering ready-to-build industrial sites with physical and/or legal infrastructure, support services, and tax incentives. Businesses that choose to locate themselves in these zones enjoy 0% tax on corporate profits during their first 10 years of operation, and only 7.5% tax over the following six years. In addition, these businesses are exempt from tax on dividends and real estate tax.

FDI Invest LT+. The Lithuanian government fosters sustainable investment by covering companies' expenditure on capital investment. Companies considering foreign direct investment in Lithuania may qualify for state funding, which is negotiated on a case-by-case basis in compliance with EU and national legislation.

Triple deduction of R&D expenditure. To promote research and development, Lithuania's government offers companies the opportunity to reduce their expenses incurred on R&D. R&D expenses are fully tax-deductible three times during the tax period in which they are incurred.

Patent Box. A reduced corporate tax rate of 5% applies to profits from copyrighted software created by Lithuanian subsidiaries, as well as inventions that meet the criteria for patentability.

Legislative package for large scale projects (LSPs)

Most notably – and unique to Lithuania – new support program for large scale investment projects that are valued at more than EUR 30M in capital expenditures and entail the creation of more than 200 jobs. The package offers significant tax incentives, including 0% of corporate tax for 20 years, and streamlines key processes in land acquisition, planning, and migration for large-scale projects.

Investments that qualify as a large scale project will be eligible for the following incentives:

0% corporate tax for 20 years	The unit in Lithuania will enjoy 0% of corporate income tax for 20 years since the day of agreement. This tax incentive combined with FDI Invest + the maximum intensity for the project can not exceed 25% on the CAPEX invested.
Recognition as a Project of State Importance	All LSPs will be given the status of Project of State Importance once the project has been added to an official list of LSPs.
Faster decision-making from public authorities	**In general, public authorities will be required to decide on matters regarding LSPs within 3 working days.**
Simplified planning requirements cutting set up time by 6-months	This means LSPs will not have to prepare detailed plans, which will cut 6 months off implementation time for the project.

Lithuania's Life Sciences industry overview

Legislative package for large scale projects (LSPs)	
Access to land plots	Servitudes necessary for the LSP's operation, including private land plots, can be arranged under the administrative act. This will ensure faster planning for large territories.
Leasing of state land	LSPs will be able lease state land without having to go through an auction.
Streamlined migration process for employees	Employees of LSP will have the right to start working in Lithuania from the day they apply for the Temporary Residence Permit, and decision on whether an employee is necessary and suitably qualified will rest with the investor.
Direct communication channel with the government	The Ministry of Economy will appoint an LSP coordinator responsible for overseeing LSP contracts and ensuring cooperation between investors and the relevant institutions. A consultative committee will be established to address key inter-institutional questions regarding LSPs.
No mandatory environmental assessment programme	It will not be mandatory for LSPs to carry out an Environmental Impact Assessment Programme.